FDA Hits Empower Pharmacy With New Warning Letter Over GLP-1 Production

What Happened

The FDA has issued a new warning letter to Empower Pharmacy, the Houston-based compounder that has grown into one of the country's largest 503B outsourcing facilities, taking issue with the company's production of GLP-1 medications. The letter, made public on September 22, 2026, is the agency's most direct step yet against a facility that sits at the center of the compounded semaglutide and tirzepatide market.

It is not the first time regulators have flagged the operation. Inspection records reported in January 2026 documented repeat quality failures at the facility, and earlier warning letters cited deficiencies in sterility assurance, environmental monitoring, and endotoxin testing for injectable drugs. The company has previously disputed some findings and pointed to corrective actions.

The stakes are unusual because of the company's scale. Reporting on the operation in 2026 described a compounder serving roughly 70,000 patients per week — a volume that turns quality-control lapses at a single facility into broad market exposure.

Who Is Affected

• Patients receiving compounded GLP-1s through telehealth platforms that source from large outsourcing facilities
• Buyers of compounded semaglutide and tirzepatide, for whom a fresh warning letter is a signal to re-check supplier documentation
• Plaintiffs in ongoing litigation against the compounder, for whom a new FDA letter is additional evidentiary material
• Researchers who purchase incretin compounds through the commercial supply chain, where facility-level quality failures ripple outward

Timeline

• April 2025 — A warning letter hits the operation as Eli Lilly sues over compounded tirzepatide
• July 2025 — An FDA inspection of the company's new outsourcing facility documents significant problems
• January 2026 — Inspection records reported by industry press show repeat quality failures
• June 2026 — Investigations describe few regulatory consequences despite years of documented violations
• August 2026 — FDA adverse-event reports involving compounded semaglutide and tirzepatide pass 1,700
• September 2026 — The new warning letter over GLP-1 production becomes public

What This Means for Researchers

A warning letter is not a shutdown order — products keep shipping while the company responds. But it is the strongest paper signal short of a recall or import alert, and a documented pattern of them across 2025 and 2026 tells you that internal quality systems, not one-off mistakes, are the issue. For research buyers the lesson is structural: volume, brand recognition, and even regulatory registration as a 503B facility do not substitute for batch-level verification. If a supplier's documentation is thin, the size of the operation makes a quality problem bigger, not smaller.

How to Verify Your Peptides

• Demand a batch-specific certificate of analysis — facility-level reputation is not a substitute for batch data
• Confirm endotoxin and sterility results for any injectable product; these are the exact systems FDA citations have targeted
• Cross-check claimed purity against an independent lab; our testing methodology guide explains the standard workflow
• For GLP-1 compounds specifically, see our semaglutide purity testing and tirzepatide HPLC testing references

Safe Alternatives

If you source GLP-1 compounds, work only with suppliers that publish current testing documentation — our vendor directory tracks exactly that. FDA-approved semaglutide and tirzepatide remain the benchmark products; compare compound profiles in our peptide database, including semaglutide and tirzepatide, and see our tirzepatide reference guide for clinical-context background.

Sources

Regulatory announcements and industry reports, including FDA warning-letter records and reporting on the compounded GLP-1 market.